Eli Lilly’s acquisition of AtaiBeckley closed on September 11, confirmed directly in the company’s own 8-K filing with the SEC. AtaiBeckley shareholders approved the merger, and Lilly’s acquisition subsidiary, Albali Acquisition Corporation, merged into the company, leaving AtaiBeckley a wholly owned Lilly subsidiary. Every AtaiBeckley director and executive officer resigned from those positions at the effective time, with the surviving company’s directors and officers now Lilly appointees, and AtaiBeckley has asked Nasdaq to suspend trading and begin the delisting and deregistration process, with the company planning to file Form 15 to terminate registration and suspend its remaining SEC reporting obligations. Two psychedelic drug programs, BPL-003 in Phase 3 and VLS-01 in Phase 2b with topline data pending, are now inside one of the world’s largest pharmaceutical companies.
What shareholders received
Each AtaiBeckley share converted into $6.75 in cash, the fixed consideration payable at closing, plus one contingent value right that could pay up to another $2.50 per share over time. That CVR is not stock and carries no equity or ownership interest: it is generally non-transferable except in limited circumstances, unregistered under the securities laws, unlisted on any exchange, and carries no voting or dividend rights, just a contractual claim to future cash if three specific milestones are met by specific deadlines. The maximum possible total per share is $9.25. The fixed cash consideration is $6.75. Those are meaningfully different numbers, and coverage of this deal, including earlier framing of it here, has not always kept that distinction as sharp as the filing itself does.
The three milestones, and how the contingent value is divided
The CVR splits into three pieces: up to $1.00 per share if a Phase 3 trial for VLS-01 is initiated prior to the fourth anniversary of closing (September 2030), up to $0.50 per share if BPL-003 wins US approval and DEA rescheduling prior to the fifth anniversary (September 2031), and up to $1.00 per share if VLS-01 itself wins US approval and rescheduling prior to the seventh anniversary (September 2033). VLS-01, the earlier-stage DMT buccal film, therefore accounts for $2.00 of the maximum $2.50 per-share CVR, while BPL-003, the 5-MeO-DMT program already in Phase 3 testing, accounts for $0.50. That distribution is notable, particularly because VLS-01 is earlier in development, but it should not be read as an asset-by-asset valuation. The filing does not explain why the milestones were weighted this way, it does not allocate the $2.8 billion upfront by asset, and milestone size can reflect development risk, timing, negotiation, and other deal terms as well as perceived upside.
What changed today versus in July
The original agreement was announced July 16 and remained subject to shareholder approval and closing. That gap is now closed. This is the difference between a signed commitment and a completed change of ownership, with immediate consequences: AtaiBeckley’s directors and executive officers resigned from those positions, with Lilly’s appointees installed in their place; the certificate of incorporation and bylaws were amended and restated; employee stock options with exercise prices below $6.75 were cashed out along with their CVR entitlement, and options with exercise prices at or above $6.75 were cancelled for no consideration; and AtaiBeckley will cease to be publicly traded following the delisting process and, after its Form 15 filing becomes effective, will no longer have the same ongoing SEC reporting obligations as a standalone public company.
How this compares with the other pharma psychedelic acquisitions tracked here
This is the largest by maximum announced transaction value of the three pharma psychedelic-related acquisitions tracked here, ahead of AbbVie’s deal for Gilgamesh’s bretisilocin program, approximately $906 million upfront plus up to $300 million in additional payments, and Otsuka’s acquisition of Transcend, $700 million at closing plus up to $525 million contingent, a maximum of $1.225 billion. It is also the last of the three to close: AbbVie completed its acquisition in October 2025, Otsuka in June 2026. With this closing, none of the three transactions tracked here remains a signed, pending agreement. All three have now closed, the acquired programs sit inside their new owners, and Lilly enters that group with the largest maximum announced transaction value and the latest integration start.
What this doesn’t resolve
A completed acquisition doesn’t change the underlying clinical and regulatory questions BPL-003 and VLS-01 still face. Phase 3 data for BPL-003 hasn’t read out yet, the acquisition does not change the clinical evidence BPL-003 must generate or the regulatory standard it must satisfy, and every one of the three CVR milestones could go unmet, in which case shareholders would receive no additional CVR payment beyond the $6.75 per share paid at closing, regardless of how the deal’s maximum value has been reported elsewhere. What’s changed is who bears the cost and controls the strategy for answering those questions: an internal Lilly program now, not a standalone public company answering to its own shareholders and disclosure obligations.